Artwork

Content provided by European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Stem Cell Research in Multiple Sclerosis

21:28
 
Share
 

Manage episode 407345653 series 3559522
Content provided by European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, explains his research comparing hematopoietic stem cell transplantation (HSCT) with existing treatments in relapsing and progressive MS.

  continue reading

45 episodes

Artwork
iconShare
 
Manage episode 407345653 series 3559522
Content provided by European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, explains his research comparing hematopoietic stem cell transplantation (HSCT) with existing treatments in relapsing and progressive MS.

  continue reading

45 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide